On February 28, 2002, Meyers, Jason K.; Rogers, Bruce N.; Groppi, Vincent E., Jr.; Piotrowski, David W.; Bodnar, Alice L.; Jacobsen, Eric Jon; Corbett, Jeffrey W. published a patent.Product Details of 400715-69-7 The title of the patent was Preparation of N-quinuclidinyl-heteroaryl amides for pharmaceutical use in the treatment of neurological disorders. And the patent contained the following:
N-quinuclidinyl-heteroaryl amides, such as I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use in the treatment of neurol. disorders, such as cognitive and attention deficit symptoms of Alzheimer’s, neurodegeneration associated with diseases such as Alzheimer’s disease, pre-senile dementia (mild cognitive impairment), or senile dementia. Thus, the hydrochloride salt of quinuclidine carboxamide II was prepared in 57% yield by an amidation reaction of (3R)-3-aminoquinuclidine hydrochloride and 5-phenylthiophene-2-carboxylic acid using di-Ph chlorophosphate and Et3N in CH2Cl2 and DMF/H2O (5:1). The prepared quinuclidinyl amides were tested for nicotinic acetylcholine receptor binding activities. The experimental process involved the reaction of Ethyl 5-(3-chlorophenyl)oxazole-2-carboxylate(cas: 400715-69-7).Product Details of 400715-69-7
The Article related to quinuclidine heteroaryl preparation neurol disorder treatment, alzheimer disease treatment quinuclidine heteroaryl preparation, dementia treatment quinuclidine heteroaryl preparation, nicotinic receptor binding quinuclidine heteroaryl preparation and other aspects.Product Details of 400715-69-7
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics